OSPREY MEDICAL INC - Announcements

0.00%

20.0¢

Currently unlisted.

Osprey Medical, Inc. is a commercial stage company, which is focused on protecting... Osprey Medical, Inc. is a commercial stage company, which is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company’s products include AVERT, AVERT Plus, the DyeVert NG, DyeVert Plus, and DyeVert Plus EZ Systems. The AVERT Plus System reduces and monitors the amount of contrast dye used in commonly performed heart and peripheral vascular procedures. The DyeVert System is a self-adjusting product that reduces the amount of contrast dye used in commonly performed heart and peripheral procedures. DyeVert interfaces with syringe-manifold systems. These technologies are available with the United States Food and Drug Administration cleared indication for dye volume reduction. Its dye reduction and monitoring technologies are designed to help physicians minimize dye usage and reduce kidney damage associated with the use of contrast media for common cardiovascular procedures.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

OSP	Appendix 4C - quarterly-OSP.AX	PRICE SENSITIVE	21/04/16	286.86KB	Share
OSP	Notice of Annual Meeting of Stockholders-OSP.AX		19/04/16	436.3KB	Share
OSP	Appendix 4G		21/03/16	289.62KB	Share
OSP	2015 Annual Report		21/03/16	4.64MB	Share
OSP	CEO Investor Presentation		03/03/16	1.66MB	Share
OSP	Preliminary Final Report and Full Year Statutory Accounts	PRICE SENSITIVE	25/02/16	376.34KB	Share
OSP	Osprey Receives FDA Clearance for Key DyeVert System Claims	PRICE SENSITIVE	08/02/16	83.27KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/16	226.9KB	Share
OSP	Appendix 3B		06/01/16	341.3KB	Share
OSP	Findings from steering committee analysis of AVERT trial	PRICE SENSITIVE	18/12/15	292.08KB	Share
OSP	Investor Newsletter December 2015		14/12/15	3.6MB	Share
OSP	Appendix 3B		04/11/15	339.36KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/15	274.91KB	Share
OSP	INVESTOR CONFERENCE CALL October 19, 2015, at 11am (AEDT)		19/10/15	102.74KB	Share
OSP	CEO Presentation		19/10/15	1017.29KB	Share
OSP	AVERT Trial Results, FDA Expanded Claims Achieved, US Launch	PRICE SENSITIVE	19/10/15	178.76KB	Share
OSP	Appendix 3B		16/10/15	250.36KB	Share
OSP	Osprey Receives DyeVert System FDA Clearance	PRICE SENSITIVE	12/10/15	79.14KB	Share
OSP	Appendix 3B		01/10/15	245.96KB	Share
OSP	Appendix 3B		01/09/15	245KB	Share
OSP	Investor Newsletter		01/09/15	1.88MB	Share
OSP	Half Year Financial Results and Revised Appendix 4D	PRICE SENSITIVE	31/08/15	665.42KB	Share
OSP	Appendix 4D and Half Year Financial Reports	PRICE SENSITIVE	31/08/15	456.69KB	Share
OSP	Appendix 3B		26/08/15	245.08KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/15	275.07KB	Share
OSP	Osprey Completes Enrolment of AVERT IDE Clinical Study	PRICE SENSITIVE	16/07/15	74.3KB	Share
OSP	CEO Investor Presentation		09/07/15	2.96MB	Share
OSP	Appendix 3B		29/05/15	344.99KB	Share
OSP	Appendix 3B		27/05/15	344.22KB	Share
OSP	Appendix 3Y		26/05/15	131.07KB	Share
OSP	Appendix 3Y		26/05/15	130.59KB	Share
OSP	Appendix 3Y		26/05/15	130.31KB	Share
OSP	Annual Meeting Results		13/05/15	143.38KB	Share
OSP	Chairman's Address and CEO's Presentation at 2015 AGM		13/05/15	1.46MB	Share
OSP	Appendix 3B		07/05/15	339KB	Share
OSP	Notice of Annual Meeting of Stockholders		24/04/15	478.35KB	Share
OSP	Appendix 4C	PRICE SENSITIVE	24/04/15	187.76KB	Share
OSP	Osprey Newsletter		24/04/15	2.02MB	Share
OSP	Appendix 3B		10/04/15	394.43KB	Share
OSP	Change in Substantial Holding		31/03/15	102.75KB	Share
OSP	Change in Substantial Holding		31/03/15	211.38KB	Share
OSP	Change in Substantial Holding		31/03/15	213.38KB	Share
OSP	Change in Substantial Holding		31/03/15	211.27KB	Share
OSP	Change in Substantial Holding		30/03/15	154.59KB	Share
OSP	Change in Substantial Holding		30/03/15	156.21KB	Share
OSP	Appendix 3B		30/03/15	402.24KB	Share
OSP	Issuance and Allotment under $16.3 Million Private Placement		30/03/15	93.59KB	Share
OSP	Cleansing Statement		30/03/15	192.01KB	Share
OSP	Annual Report to shareholders		24/03/15	694.02KB	Share
OSP	Reinstatement of Official Quotation	PRICE SENSITIVE	23/03/15	63.62KB	Share
OSP	Reinstatement of Official Quotation	PRICE SENSITIVE	23/03/15	63.62KB	Share
OSP	Osprey Announces $16.3 Private Placement	PRICE SENSITIVE	23/03/15	93.72KB	Share
OSP	Osprey Announces $16.3 Private Placement	PRICE SENSITIVE	23/03/15	93.72KB	Share
OSP	Suspension from Official Quotation	PRICE SENSITIVE	19/03/15	223.57KB	Share
OSP	CEO Investor Presentation		17/03/15	2.01MB	Share
OSP	Trading Halt	PRICE SENSITIVE	17/03/15	196.52KB	Share
OSP	Annual Meeting of Stockholders		16/03/15	101.52KB	Share
OSP	Preliminary Final Report and Full Year Financial Results	PRICE SENSITIVE	18/02/15	402.04KB	Share
OSP	Appendix 3B		11/02/15	392.83KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	239.87KB	Share
OSP	AVERT Contrast Monitoring Technology Receives FDA Clearance	PRICE SENSITIVE	16/12/14	101.24KB	Share
OSP	Change in substantial holding		15/12/14	102.37KB	Share
OSP	CEO Investor Presentation		06/11/14	5.16MB	Share
OSP	Osprey Newsletter		03/11/14	2.25MB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	20/10/14	198.97KB	Share
OSP	CEO Investor Presentation - 18 September 2014		18/09/14	1.09MB	Share
OSP	AVERT to be presented at leading Cardiovascular Conference		15/09/14	1.73MB	Share
OSP	Half Yearly Report and Accounts	PRICE SENSITIVE	22/08/14	476.85KB	Share
OSP	CEO Presentation August 2014		04/08/14	1.32MB	Share
OSP	Investor Newsletter August 2014		04/08/14	2.62MB	Share
OSP	Physicians use AVERT in peripheral artery disease procedures	PRICE SENSITIVE	04/08/14	75.71KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	22/07/14	182.98KB	Share
OSP	US FDA Clearance for the AVERT System	PRICE SENSITIVE	17/06/14	108.33KB	Share
OSP	ViMove features on Channel 9 - A Current Affair		23/05/14	85.68KB	Share
OSP	Appendix 3Y		20/05/14	129.85KB	Share
OSP	Appendix 3Y		19/05/14	128.02KB	Share
OSP	Appendix 3Y		19/05/14	130.38KB	Share
OSP	Appendix 3Y		19/05/14	130.74KB	Share
OSP	Appendix 3B		19/05/14	353.38KB	Share
OSP	Annual Meeting Results		14/05/14	105.86KB	Share
OSP	Chairman's address & CEO's presentation at 2014 AGM		14/05/14	1.14MB	Share
OSP	CEO May 2014 Presentation		12/05/14	1.02MB	Share
OSP	Release of Securities		02/05/14	433.27KB	Share
OSP	Appendix 4C	PRICE SENSITIVE	24/04/14	155.75KB	Share
OSP	Release of Securities from Escrow		11/04/14	82.18KB	Share
OSP	Notice of Annual Meeting of Stockholders		11/04/14	857.82KB	Share
OSP	Limb Recovery System Presented at Major Medical Conference	PRICE SENSITIVE	10/04/14	65.4KB	Share
OSP	CEO March 2014 Presentation		18/03/14	5.34MB	Share
OSP	Appendix 3B		18/03/14	317.28KB	Share
OSP	2013 Annual Report		17/03/14	2.61MB	Share
OSP	Change in Address of Australian Registered Office		17/03/14	69.5KB	Share
OSP	Annual Meeting of Stockholders		12/03/14	71.24KB	Share
OSP	Osprey March 2014 Investor Newsletter		12/03/14	2.03MB	Share
OSP	Preliminary Final Report and Annual Financial Statements	PRICE SENSITIVE	25/02/14	441.83KB	Share
OSP	Appendix 3B		14/02/14	315.83KB	Share
OSP	Appendix 4C - quarterly	PRICE SENSITIVE	23/01/14	88.18KB	Share
OSP	Appendix 3B		22/01/14	321.83KB	Share
OSP	Enrolment of first patient in the AVERT IDE Clinical Study	PRICE SENSITIVE	07/01/14	81.42KB	Share
OSP	Publication of results from AVERT pilot clinical trial	PRICE SENSITIVE	02/01/14	323.06KB	Share
OSP	Appendix 3B		23/12/13	327.88KB	Share

OSP Appendix 4C - quarterly-OSP.AX
21/04/16	PRICE SENSITIVE	286.86KB	Share
OSP Notice of Annual Meeting of Stockholders-OSP.AX
19/04/16		436.3KB	Share
OSP Appendix 4G
21/03/16		289.62KB	Share
OSP 2015 Annual Report
21/03/16		4.64MB	Share
OSP CEO Investor Presentation
03/03/16		1.66MB	Share
OSP Preliminary Final Report and Full Year Statutory Accounts
25/02/16	PRICE SENSITIVE	376.34KB	Share
OSP Osprey Receives FDA Clearance for Key DyeVert System Claims
08/02/16	PRICE SENSITIVE	83.27KB	Share
OSP Appendix 4C - quarterly
28/01/16	PRICE SENSITIVE	226.9KB	Share
OSP Appendix 3B
06/01/16		341.3KB	Share
OSP Findings from steering committee analysis of AVERT trial
18/12/15	PRICE SENSITIVE	292.08KB	Share
OSP Investor Newsletter December 2015
14/12/15		3.6MB	Share
OSP Appendix 3B
04/11/15		339.36KB	Share
OSP Appendix 4C - quarterly
30/10/15	PRICE SENSITIVE	274.91KB	Share
OSP INVESTOR CONFERENCE CALL October 19, 2015, at 11am (AEDT)
19/10/15		102.74KB	Share
OSP CEO Presentation
19/10/15		1017.29KB	Share
OSP AVERT Trial Results, FDA Expanded Claims Achieved, US Launch
19/10/15	PRICE SENSITIVE	178.76KB	Share
OSP Appendix 3B
16/10/15		250.36KB	Share
OSP Osprey Receives DyeVert System FDA Clearance
12/10/15	PRICE SENSITIVE	79.14KB	Share
OSP Appendix 3B
01/10/15		245.96KB	Share
OSP Appendix 3B
01/09/15		245KB	Share
OSP Investor Newsletter
01/09/15		1.88MB	Share
OSP Half Year Financial Results and Revised Appendix 4D
31/08/15	PRICE SENSITIVE	665.42KB	Share
OSP Appendix 4D and Half Year Financial Reports
31/08/15	PRICE SENSITIVE	456.69KB	Share
OSP Appendix 3B
26/08/15		245.08KB	Share
OSP Appendix 4C - quarterly
30/07/15	PRICE SENSITIVE	275.07KB	Share
OSP Osprey Completes Enrolment of AVERT IDE Clinical Study
16/07/15	PRICE SENSITIVE	74.3KB	Share
OSP CEO Investor Presentation
09/07/15		2.96MB	Share
OSP Appendix 3B
29/05/15		344.99KB	Share
OSP Appendix 3B
27/05/15		344.22KB	Share
OSP Appendix 3Y
26/05/15		131.07KB	Share
OSP Appendix 3Y
26/05/15		130.59KB	Share
OSP Appendix 3Y
26/05/15		130.31KB	Share
OSP Annual Meeting Results
13/05/15		143.38KB	Share
OSP Chairman's Address and CEO's Presentation at 2015 AGM
13/05/15		1.46MB	Share
OSP Appendix 3B
07/05/15		339KB	Share
OSP Notice of Annual Meeting of Stockholders
24/04/15		478.35KB	Share
OSP Appendix 4C
24/04/15	PRICE SENSITIVE	187.76KB	Share
OSP Osprey Newsletter
24/04/15		2.02MB	Share
OSP Appendix 3B
10/04/15		394.43KB	Share
OSP Change in Substantial Holding
31/03/15		102.75KB	Share
OSP Change in Substantial Holding
31/03/15		211.38KB	Share
OSP Change in Substantial Holding
31/03/15		213.38KB	Share
OSP Change in Substantial Holding
31/03/15		211.27KB	Share
OSP Change in Substantial Holding
30/03/15		154.59KB	Share
OSP Change in Substantial Holding
30/03/15		156.21KB	Share
OSP Appendix 3B
30/03/15		402.24KB	Share
OSP Issuance and Allotment under $16.3 Million Private Placement
30/03/15		93.59KB	Share
OSP Cleansing Statement
30/03/15		192.01KB	Share
OSP Annual Report to shareholders
24/03/15		694.02KB	Share
OSP Reinstatement of Official Quotation
23/03/15	PRICE SENSITIVE	63.62KB	Share
OSPReinstatement of Official Quotation
23/03/15	PRICE SENSITIVE	63.62KB	Share
OSP Osprey Announces $16.3 Private Placement
23/03/15	PRICE SENSITIVE	93.72KB	Share
OSPOsprey Announces $16.3 Private Placement
23/03/15	PRICE SENSITIVE	93.72KB	Share
OSP Suspension from Official Quotation
19/03/15	PRICE SENSITIVE	223.57KB	Share
OSP CEO Investor Presentation
17/03/15		2.01MB	Share
OSP Trading Halt
17/03/15	PRICE SENSITIVE	196.52KB	Share
OSP Annual Meeting of Stockholders
16/03/15		101.52KB	Share
OSP Preliminary Final Report and Full Year Financial Results
18/02/15	PRICE SENSITIVE	402.04KB	Share
OSP Appendix 3B
11/02/15		392.83KB	Share
OSP Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	239.87KB	Share
OSP AVERT Contrast Monitoring Technology Receives FDA Clearance
16/12/14	PRICE SENSITIVE	101.24KB	Share
OSP Change in substantial holding
15/12/14		102.37KB	Share
OSP CEO Investor Presentation
06/11/14		5.16MB	Share
OSP Osprey Newsletter
03/11/14		2.25MB	Share
OSP Appendix 4C - quarterly
20/10/14	PRICE SENSITIVE	198.97KB	Share
OSP CEO Investor Presentation - 18 September 2014
18/09/14		1.09MB	Share
OSP AVERT to be presented at leading Cardiovascular Conference
15/09/14		1.73MB	Share
OSP Half Yearly Report and Accounts
22/08/14	PRICE SENSITIVE	476.85KB	Share
OSP CEO Presentation August 2014
04/08/14		1.32MB	Share
OSP Investor Newsletter August 2014
04/08/14		2.62MB	Share
OSP Physicians use AVERT in peripheral artery disease procedures
04/08/14	PRICE SENSITIVE	75.71KB	Share
OSP Appendix 4C - quarterly
22/07/14	PRICE SENSITIVE	182.98KB	Share
OSP US FDA Clearance for the AVERT System
17/06/14	PRICE SENSITIVE	108.33KB	Share
OSPViMove features on Channel 9 - A Current Affair
23/05/14		85.68KB	Share
OSPAppendix 3Y
20/05/14		129.85KB	Share
OSPAppendix 3Y
19/05/14		128.02KB	Share
OSPAppendix 3Y
19/05/14		130.38KB	Share
OSPAppendix 3Y
19/05/14		130.74KB	Share
OSPAppendix 3B
19/05/14		353.38KB	Share
OSPAnnual Meeting Results
14/05/14		105.86KB	Share
OSPChairman's address & CEO's presentation at 2014 AGM
14/05/14		1.14MB	Share
OSPCEO May 2014 Presentation
12/05/14		1.02MB	Share
OSPRelease of Securities
02/05/14		433.27KB	Share
OSPAppendix 4C
24/04/14	PRICE SENSITIVE	155.75KB	Share
OSPRelease of Securities from Escrow
11/04/14		82.18KB	Share
OSPNotice of Annual Meeting of Stockholders
11/04/14		857.82KB	Share
OSPLimb Recovery System Presented at Major Medical Conference
10/04/14	PRICE SENSITIVE	65.4KB	Share
OSPCEO March 2014 Presentation
18/03/14		5.34MB	Share
OSPAppendix 3B
18/03/14		317.28KB	Share
OSP2013 Annual Report
17/03/14		2.61MB	Share
OSPChange in Address of Australian Registered Office
17/03/14		69.5KB	Share
OSPAnnual Meeting of Stockholders
12/03/14		71.24KB	Share
OSPOsprey March 2014 Investor Newsletter
12/03/14		2.03MB	Share
OSPPreliminary Final Report and Annual Financial Statements
25/02/14	PRICE SENSITIVE	441.83KB	Share
OSPAppendix 3B
14/02/14		315.83KB	Share
OSPAppendix 4C - quarterly
23/01/14	PRICE SENSITIVE	88.18KB	Share
OSPAppendix 3B
22/01/14		321.83KB	Share
OSPEnrolment of first patient in the AVERT IDE Clinical Study
07/01/14	PRICE SENSITIVE	81.42KB	Share
OSPPublication of results from AVERT pilot clinical trial
02/01/14	PRICE SENSITIVE	323.06KB	Share
OSPAppendix 3B
23/12/13		327.88KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

OSPREY MEDICAL INC - Announcements

Corporate SpotlightNot Yet Available

Announcements

Top Stories

Corporate Spotlight
Not Yet Available